ABBV-1758 for Alzheimer’s Disease Treatment
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
Recruiting
Phase 1
Phase 2
Interventional Study
Alzheimer's Disease
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 – 90
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 210 (estimated)
- Sponsor
- AbbVie · Industry
Who this trial is looking for
This trial is looking for people with Alzheimer's disease to test a new drug called ABBV-1758. Participants will receive injections of the drug or a placebo every 4 weeks for 24 weeks.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with Alzheimer's disease.
- I have a Mini-Mental State Examination (MMSE) score of 20 or higher.
- I have a positive amyloid PET scan indicating significant amyloid pathology.
- I can provide timely plasma biomarker results if needed.
You may not be able to join if
- I have another serious condition that isn't well-controlled.
- I have had prior treatment with ABBV-1758 or anti-amyloid beta monoclonal antibodies.
- I have brain MRI findings that indicate significant issues, such as swelling or bleeding.
- I have had a MRI that shows another cause for my dementia.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independe…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participants meeting all the following criteria for Alzheimer's disease (AD):
* In regions where timely testing is feasible (e.g., results available within 4 weeks of Visit 1), plasma biomarker that is predictive of elevated brain amyloid at Screening for participants that …
Contacts